Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have described exocyclic amino quinazoline derivatives acting as GTPase KRAS inhibitors, particularly KRAS (G12D mutant) inhibitors, reported to be useful for the treatment of cancer.
Chengdu Baiyu Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors acting as pyroptosis inhibitors reported to be useful for the treatment of cancer, autoimmune, cardiovascular, endocrine, respiratory, renal, neurological and gastrointestinal disorders, among others.
George Washington University has described N-ACYL fosmidomycin prodrug analogues acting as 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr; IspC) (Mycobacterium tuberculosis) and Dxr (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria and tuberculosis.
University College Cardiff has divulged heteroaryl compounds acting as GABA(A) receptor subunit α5 (GABRA5) negative allosteric modulators reported to be useful for the treatment of cognitive disorders.
Researchers at St. Louis University, Washington University in St. Louis, and Fimbrion Therapeutics Inc. have identified ubiquinol-cytochrome C reductase cytochrome b subunit (qcrB) (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis.